Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer

NCT02339532 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02339532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02339532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
July 8, 2024
Enrollment
86 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer